Table 3.

Clinical outcomes according to the calculated threshold of hs-cTn I ≥ 12 ng/L.

	Univariate analysis				Multivariate analysis
	Hs-cTn I < 12 ng/L (N = 9647)	Hs-cTn I ≥ 12 ng/L (N = 2768)	Unadjusted HR (95% CI)	p-Value	aAdjusted HR (95% CI)	p-Value
30-day mortality	215 (2.2)	127 (4.6)	1.88 (1.51–2.33)	< 0.001	1.54 (1.23–1.93)	< 0.001
In-hospital mortality	291 (3.0)	175 (6.3)	1.53 (1.28–1.85)	< 0.001	1.28 (1.05–1.55)	0.01
MINS	853/5007 (17.0)	631/1608 (39.2)

Data are presented as n (%) or mean (± standard deviation).

HR hazard ration; CI confidential interval; hs-cTn high-sensitivity cardiac troponin; MINS myocardial injury after noncardiac surgery.

^aCovariates include sex, chronic kidney disease, previous stroke, preoperative hemoglobin, statin, beta-blocker, calcium channel blocker, renin–angiotensin–aldosterone system inhibitor, emergency surgery, general anesthesia, operative duration, and intraoperative inotropic use and red cell transfusion.